Pharmacyclics completes enrollment in phase III Ibrutinib CLL study – pharmabiz.com
Pharmacyclics completes enrollment in phase III Ibrutinib CLL studypharmabiz.com… planned 110 patients in the phase II single-arm study using ibrutinib in patients with mantle cell lymphoma (MCL) who progress after bortezomib therapy and have receive…


